

 <p>INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98)</p> <p>SHEET 1 OF 1</p>	ATTORNEY DOCKET 25352-0029	APPLICATION NO. 09/977,059
	APPLICANT(S) Prasad V.V.S.V. Mancham et al.	
	FILING DATE October 11, 2001	ART UNIT 1617

U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION

OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
MD	19	Schütt et al., "The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells", <i>Diabetologia</i> , 43 , 1145-1148 (2000)
	20	Saint-Marc et al., "Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy", <i>AIDS</i> , 13 (8), 1000-1002 (1999). ✓
	21	"AACTG recommendations for metabolic problems", <i>AIDS ALERT</i> , p.6 (January 2003) ✓
MD	22	Tanwani et al., "Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection", <i>Southern Medical Journal</i> , 96 (2), 180-188 (2003)

EXAMINER'S SIGNATURE 	DATE CONSIDERED 06/10/03
---	-----------------------------

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered.
Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).